Display options
Cite
Brækkan SK, Caram-Deelder C, Siegerink B, et al. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost. 2017;1(1):112-119doi: 10.1002/rth2.12003.
Brækkan, S. K., Caram-Deelder, C., Siegerink, B., van Hylckama Vlieg, A., le Cessie, S., Rosendaal, F. R., Cannegieter, S. C., & Lijfering, W. M. (2017). Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Research and practice in thrombosis and haemostasis, 1(1), 112-119. https://doi.org/10.1002/rth2.12003
Brækkan, Sigrid K, et al. "Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study." Research and practice in thrombosis and haemostasis vol. 1,1 (2017): 112-119. doi: https://doi.org/10.1002/rth2.12003
Brækkan SK, Caram-Deelder C, Siegerink B, van Hylckama Vlieg A, le Cessie S, Rosendaal FR, Cannegieter SC, Lijfering WM. Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study. Res Pract Thromb Haemost. 2017 May 25;1(1):112-119. doi: 10.1002/rth2.12003. eCollection 2017 Jul. PMID: 30046679; PMCID: PMC6058203.
Copy Download .nbib Format: NLM
Share it on

Res Pract Thromb Haemost. 2017 May 25;1(1):112-119. doi: 10.1002/rth2.12003. eCollection 2017 Jul.

Statin use and risk of recurrent venous thrombosis: results from the MEGA follow-up study.

Research and practice in thrombosis and haemostasis

Sigrid K Brækkan, Camila Caram-Deelder, Bob Siegerink, Astrid van Hylckama Vlieg, Saskia le Cessie, Frits R Rosendaal, Suzanne C Cannegieter, Willem M Lijfering

Affiliations

  1. Department of Clinical Epidemiology Leiden University Medical Center Leiden the Netherlands.
  2. K.G Jebsen Thrombosis Research and Expertise Center (TREC) University of Tromsø Tromsø Norway.
  3. Center for Clinical Transfusion Research Sanquin Research Leiden the Netherlands.
  4. Einthoven Laboratory of Experimental Vascular Medicine Leiden University Medical Center Leiden the Netherlands.
  5. Center for Stroke Research Berlin Charité Universitätsmedizin Berlin Berlin Germany.
  6. Department of Medical Statistics and Bioinformatics Leiden University Medical Center Leiden the Netherlands.

PMID: 30046679 PMCID: PMC6058203 DOI: 10.1002/rth2.12003

Abstract

INTRODUCTION: Whether statin use after first venous thrombosis reduces the risk of recurrence is uncertain. Therefore, we aimed to examine the risk of recurrent venous thrombosis in statin users vs non-users.

METHODS: Patients with a first venous thrombosis were recruited from the MEGA follow-up study. Information on statin use was obtained by linkage to the Dutch Foundation for Pharmaceutical Statistics register. Linkage was successful in 54% of all patients (n = 2,547). Cox-regression models with statin-exposure as a time-dependent co-variate were used to estimate hazard ratios (HR) with 95% confidence intervals (CI 95) for recurrence.

RESULTS: Statin therapy was continued in 153 (6.0%) patients and initiated in 233 (9.1%) patients during a median follow-up of 5.7 years. There were 367 recurrent venous thrombotic events, of which 32 occurred among statin users. Incident statin use was associated with 22% reduced risk of recurrence after multivariable adjustments (HR 0.78, CI 95: 0.46-1.31), and 13% reduced risk after propensity score adjustment (HR 0.87, CI 95: 0.52-1.47). Statin use seemed not to have an effect on recurrence in patients with an unprovoked first event (multivariable HR 1.03, CI 95: 0.54-1.98), but the statistical power was low due to few events and the results must be interpreted with caution. In general, the risk estimates were slightly attenuated when prevalent users were included in the analyses.

CONCLUSION: Our findings suggest that statins may have a modest decreasing effect on the risk of recurrent venous thrombosis. While we took care to minimize bias and confounding, the causality of the association is still unsettled.

Keywords: deep vein thrombosis; pulmonary embolism; recurrence; statins; venous thrombosis

References

  1. Am J Epidemiol. 2015 Nov 15;182(10):826-33 - PubMed
  2. Am J Epidemiol. 2012 Feb 15;175(4):250-62 - PubMed
  3. Lancet. 1999 Apr 3;353(9159):1167-73 - PubMed
  4. J Thromb Haemost. 2007 Nov;5(11):2186-92 - PubMed
  5. BMJ Open. 2013 Nov 07;3(11):e003135 - PubMed
  6. Eur Heart J. 2013 Jun;34(24):1800-6 - PubMed
  7. J Thromb Haemost. 2014 Aug;12(8):1207-15 - PubMed
  8. Thromb Haemost. 2016 Jun 2;115(6):1220-8 - PubMed
  9. N Engl J Med. 2009 Apr 30;360(18):1851-61 - PubMed
  10. J Thromb Haemost. 2016 Jul;14(7):1384-92 - PubMed
  11. J Am Coll Cardiol. 2014 Jul 1;63(25 Pt B):2889-934 - PubMed
  12. QJM. 2011 Feb;104(2):109-24 - PubMed
  13. JAMA. 2005 May 18;293(19):2352-61 - PubMed
  14. Eur J Epidemiol. 2010 Apr;25(4):245-51 - PubMed
  15. J Thromb Haemost. 2007 Apr;5(4):692-9 - PubMed
  16. Lancet. 2010 Feb 27;375(9716):735-42 - PubMed
  17. Eur Heart J. 2010 May;31(10):1248-56 - PubMed
  18. Thromb Res. 2012 Dec;130(6):859-63 - PubMed
  19. PLoS Med. 2012;9(9):e1001310 - PubMed
  20. J Thromb Haemost. 2015 Oct;13(10):1823-32 - PubMed
  21. JAMA. 2008 Mar 19;299(11):1306-14 - PubMed
  22. Circulation. 2004 Jul 13;110(2):227-39 - PubMed
  23. Am J Epidemiol. 2006 Jun 15;163(12):1149-56 - PubMed
  24. Lancet. 2007 Nov 24;370(9601):1781-90 - PubMed
  25. Lancet. 2007 Nov 24;370(9601):1773-9 - PubMed
  26. JAMA. 2005 Feb 9;293(6):715-22 - PubMed
  27. Epidemiology. 2004 Sep;15(5):615-25 - PubMed
  28. Circulation. 2011 Sep 27;124(13):1435-41 - PubMed

Publication Types